Form 8-K · Current Report · Filed 2025-09-29
Metsera Announces Positive Phase 2b Results for MET-097i
On September 29, 2025, Metsera, Inc. announced positive topline data from two Phase 2b trials of MET-097i, a GLP-1 receptor agonist. In VESPER-1, the drug demonstrated mean placebo-subtracted weight loss of up to 14.1% after 28 weekly doses, with potentially class-leading tolerability. The company plans to initiate a global Phase 3 program in late 2025 based on these results.
- Filer
- MTSR MTSR
- Filed
- Accession
- 0001193125-25-223440
- CIK
- 0002040807
- Signal
- Medium impact
- Source
- Official filing on sec.gov ↗
Items reported
Regulation FD Disclosure
Other Events
Market reaction
Close before filing
$52.25
Next session
+0.2%
Since filing
+34.9%
Latest close
$70.50
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from MTSR reporting the same item, with the next session's move:
Never miss another MTSR filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.